{"transactions":[{"id":1712286,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2023-12-13T17:30:08.000Z","date":"2023-12-11","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of December 11, 2023; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on March 11, 2025 and ending on December 11, 2026."}],"balance_after":20000,"derivative":{"exercise_price":3.88,"expiration_date":"2033-12-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001683168-23-008824","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1224096/000168316823008824/ownership.xml","form_type":"4"}},{"id":2316451,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2022-03-28T17:16:48.000Z","date":"2022-03-24","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of March 24, 2022; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on June 24, 2023 and ending on March 24, 2025."}],"balance_after":100000,"derivative":{"exercise_price":1.12,"expiration_date":"2032-03-24","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001683168-22-002000","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1224096/000168316822002000/ownership.xml","form_type":"4"}},{"id":2776113,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2021-03-22T17:30:19.000Z","date":"2021-03-18","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of March 18, 2021; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on June 18, 2022 and ending on March 18, 2024."}],"balance_after":100000,"derivative":{"exercise_price":2.6,"expiration_date":"2031-03-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001683168-21-001018","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1224096/000168316821001018/ownership.xml","form_type":"4"}},{"id":3349564,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2019-12-06T18:30:27.000Z","date":"2019-12-04","kind":"grant","acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the options will vest and become exercisable as follows: 76,666 shares shall vest on the first anniversary of December 4, 2019 (\"Vesting Start Date\"); 76,667 shares shall vest on the second anniversary of the Vesting Start Date; and 76,667 shares shall vest on the third anniversary of the Vesting Start Date."}],"balance_after":230000,"derivative":{"exercise_price":1.31,"expiration_date":"2029-12-04","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001683168-19-003915","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1224096/000168316819003915/ownership.xml","form_type":"4"}},{"id":4037412,"issuer":{"id":167746,"kind":"organization","name":"MABVAX THERAPEUTICS HOLDINGS, INC.","symbol":"MBVX"},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-02-23T15:45:49.000Z","date":"2018-02-21","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Option award is partial compensation for service as a director."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Option award is partial compensation for service as a director."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option Shares shall vest on a monthly basis after the commencement date until fully vested on the one year anniversary of the commencement date."}],"balance_after":35000,"derivative":{"exercise_price":2.04,"expiration_date":"2028-02-21","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-18-000308","document":"form4-02232018_120235.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1109196/000141588918000308/form4-02232018_120235.xml","form_type":"4"}},{"id":4091239,"issuer":{"id":167746,"kind":"organization","name":"MABVAX THERAPEUTICS HOLDINGS, INC.","symbol":"MBVX"},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-24T19:13:26.000Z","date":"2018-01-24","kind":"sale","acquired":false,"shares":17998,"price":0.84,"value":15118.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a portion of the number of shares required to be sold by the reporting person to cover estimated tax obligations in connection with the vesting of the RSUs of the reporting person. This sale is mandated by the Issuer's election, as approved by the Board of Directors, under the equity incentive plan to require satisfaction of estimated tax obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.86 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":64558,"source":{"system":"sec-edgar","filing":"0001415889-18-000120","document":"form4-01242018_040112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1109196/000141588918000120/form4-01242018_040112.xml","form_type":"4"}},{"id":4091238,"issuer":{"id":167746,"kind":"organization","name":"MABVAX THERAPEUTICS HOLDINGS, INC.","symbol":"MBVX"},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-24T19:13:26.000Z","date":"2018-01-23","kind":"sale","acquired":false,"shares":17444,"price":0.87,"value":15176.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a portion of the number of shares required to be sold by the reporting person to cover estimated tax obligations in connection with the vesting of the RSUs of the reporting person. This sale is mandated by the Issuer's election, as approved by the Board of Directors, under the equity incentive plan to require satisfaction of estimated tax obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.85 to $0.89 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":82556,"source":{"system":"sec-edgar","filing":"0001415889-18-000120","document":"form4-01242018_040112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1109196/000141588918000120/form4-01242018_040112.xml","form_type":"4"}},{"id":4100613,"issuer":{"id":167746,"kind":"organization","name":"MABVAX THERAPEUTICS HOLDINGS, INC.","symbol":"MBVX"},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2018-01-12T17:23:47.000Z","date":"2018-01-08","kind":"exercise","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vested on January 8, 2018, subject to the Reporting Person's continued employment or service with the Issuer on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vested on January 8, 2018, subject to the Reporting Person's continued employment or service with the Issuer on each such vesting date."}],"balance_after":1543,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-18-000052","document":"form4-01122018_020133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1109196/000141588918000052/form4-01122018_020133.xml","form_type":"4"}},{"id":4100612,"issuer":{"id":167746,"kind":"organization","name":"MABVAX THERAPEUTICS HOLDINGS, INC.","symbol":"MBVX"},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-12T17:23:47.000Z","date":"2018-01-08","kind":"exercise","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents conversion of restricted stock units into common stock upon vesting of such units granted on September 15, 2017 and October 2, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents conversion of restricted stock units into common stock upon vesting of such units granted on September 15, 2017 and October 2, 2017."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001415889-18-000052","document":"form4-01122018_020133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1109196/000141588918000052/form4-01122018_020133.xml","form_type":"4"}},{"id":4178406,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Options","published_at":"2017-10-30T21:09:20.000Z","date":"2017-10-26","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option will vest and become exercisable as follows: 41,666 shares shall vest on the first anniversary of October 26, 2017 (the \"Vesting Start Date\"); 41,667 shares shall vest on the second anniversary of the Vesting Start Date; 41,667 shares shall vest on the third anniversary of the Vesting Start Date; 100,000 shares shall vest upon the achievement of key clinical milestones for XBIO-101; and 25,000 shares shall vest upon the achievement of key development milestones related to PSA. The Reporting Owner may not exercise any of the shares under the option if and until the Issuer receives shareholder approval of an increase in the number of shares of common stock authorized under the Company's equity incentive plan on or prior to October 11, 2018."}],"balance_after":250000,"derivative":{"exercise_price":2.11,"expiration_date":"2027-10-26","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001662252-17-000220","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1224096/000166225217000220/form4.xml","form_type":"4"}},{"id":4178405,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2017-10-30T21:09:20.000Z","date":"2017-10-26","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents the grant of a restricted stock unit (\"RSU\") award. Each RSU represents the right to receive one share of the Issuer's common stock at vesting. The shares underlying the RSUs will vest and become exercisable as follows: one-third on the first anniversary of October 26, 2017 (the \"Vesting Start Date\"); one-third on the second anniversary of the Vesting Start Date; and one-third on the third anniversary of the Vesting Start Date."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001662252-17-000220","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1224096/000166225217000220/form4.xml","form_type":"4"}},{"id":4192416,"issuer":{"id":167746,"kind":"organization","name":"MABVAX THERAPEUTICS HOLDINGS, INC.","symbol":"MBVX"},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2017-10-04T06:25:14.000Z","date":"2017-10-02","kind":"grant","acquired":true,"shares":75790,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Grants of restricted stock units convert on a one-for-one basis into common stock and vest on January 8, 2018 or earlier under provisions of the Company's current equity incentive plan and individual employment agreements. Grants to management and board of directors are intended to provide incentives to remain at the company during activities related to evaluation of strategic options with an investment advisory bank intended on improving shareholder value and in consideration for potential success resulting from those efforts."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grants of restricted stock units convert on a one-for-one basis into common stock and vest on January 8, 2018 or earlier under provisions of the Company's current equity incentive plan and individual employment agreements. Grants to management and board of directors are intended to provide incentives to remain at the company during activities related to evaluation of strategic options with an investment advisory bank intended on improving shareholder value and in consideration for potential success resulting from those efforts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grants of restricted stock units convert on a one-for-one basis into common stock and vest on January 8, 2018 or earlier under provisions of the Company's current equity incentive plan and individual employment agreements. Grants to management and board of directors are intended to provide incentives to remain at the company during activities related to evaluation of strategic options with an investment advisory bank intended on improving shareholder value and in consideration for potential success resulting from those efforts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Grants of restricted stock units convert on a one-for-one basis into common stock and vest on January 8, 2018 or earlier under provisions of the Company's current equity incentive plan and individual employment agreements. Grants to management and board of directors are intended to provide incentives to remain at the company during activities related to evaluation of strategic options with an investment advisory bank intended on improving shareholder value and in consideration for potential success resulting from those efforts."}],"balance_after":75790,"derivative":{"underlying":"Common Stock","underlying_shares":75790},"source":{"system":"sec-edgar","filing":"0001415889-17-001618","document":"form4-10042017_031003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1109196/000141588917001618/form4-10042017_031003.xml","form_type":"4"}},{"id":4207390,"issuer":{"id":167746,"kind":"organization","name":"MABVAX THERAPEUTICS HOLDINGS, INC.","symbol":"MBVX"},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2017-09-18T17:20:38.000Z","date":"2017-09-15","kind":"grant","acquired":true,"shares":24210,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Grants of restricted stock units convert on a one-for-one basis into common stock and vest on January 8, 2018 or earlier under provisions of the Company's current equity incentive plan and individual employment agreements.  Grants to management and board of directors are intended to provide incentives to remain at the company during activities related to evaluation of strategic options with an investment advisory bank intended on improving shareholder value and in consideration for potential success resulting from those efforts."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grants of restricted stock units convert on a one-for-one basis into common stock and vest on January 8, 2018 or earlier under provisions of the Company's current equity incentive plan and individual employment agreements.  Grants to management and board of directors are intended to provide incentives to remain at the company during activities related to evaluation of strategic options with an investment advisory bank intended on improving shareholder value and in consideration for potential success resulting from those efforts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grants of restricted stock units convert on a one-for-one basis into common stock and vest on January 8, 2018 or earlier under provisions of the Company's current equity incentive plan and individual employment agreements.  Grants to management and board of directors are intended to provide incentives to remain at the company during activities related to evaluation of strategic options with an investment advisory bank intended on improving shareholder value and in consideration for potential success resulting from those efforts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Grants of restricted stock units convert on a one-for-one basis into common stock and vest on January 8, 2018 or earlier under provisions of the Company's current equity incentive plan and individual employment agreements.  Grants to management and board of directors are intended to provide incentives to remain at the company during activities related to evaluation of strategic options with an investment advisory bank intended on improving shareholder value and in consideration for potential success resulting from those efforts."}],"balance_after":24210,"derivative":{"underlying":"Common Stock","underlying_shares":24210},"source":{"system":"sec-edgar","filing":"0001415889-17-001505","document":"form4-09182017_050927.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1109196/000141588917001505/form4-09182017_050927.xml","form_type":"4"}},{"id":4282464,"issuer":{"id":167746,"kind":"organization","name":"MABVAX THERAPEUTICS HOLDINGS, INC.","symbol":"MBVX"},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2017-06-14T16:08:00.000Z","date":"2017-06-12","kind":"grant","acquired":true,"shares":20000,"price":1.57,"value":31400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatic Annual Grant to Non-Employee Director pursuant to the Issuer's Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option vests and becomes exercisable one year after the date of grant, subject to recipient's continued service on the Company's Board of Directors."}],"balance_after":20000,"derivative":{"exercise_price":1.57,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-17-000980","document":"form4-06142017_010649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1109196/000141588917000980/form4-06142017_010649.xml","form_type":"4"}},{"id":4308515,"issuer":{"id":167746,"kind":"organization","name":"MABVAX THERAPEUTICS HOLDINGS, INC.","symbol":"MBVX"},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2017-05-23T20:10:31.000Z","date":"2017-05-19","kind":"grant","acquired":true,"shares":50000,"price":1.8,"value":90000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested and exercisable and was issued pursuant to conditions of the Letter Agreement, dated May 15, 2017, by and between the Company and the lead investor in connection with the Company's public offering completed on May 19, 2017, and filed with the Securities and Exchange Commission on May 22, 2017 as Exhibit A of Exhibit 10.2 of the Company's Quarterly Report on Form 10-Q."}],"balance_after":50000,"derivative":{"exercise_price":1.8,"expiration_date":"2027-05-19","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-17-000844","document":"form4-05232017_050520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1109196/000141588917000844/form4-05232017_050520.xml","form_type":"4"}},{"id":4508171,"issuer":{"id":167746,"kind":"organization","name":"MABVAX THERAPEUTICS HOLDINGS, INC.","symbol":"MBVX"},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2017-01-03T21:10:11.000Z","date":"2017-01-01","kind":"grant","acquired":true,"shares":2300,"price":3.38,"value":7774.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such Options shall vest in equal annual installments over a three year period."}],"balance_after":2300,"derivative":{"exercise_price":3.38,"expiration_date":"2027-01-01","underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0001415889-17-000027","document":"form4-01032017_060159.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1109196/000141588917000027/form4-01032017_060159.xml","form_type":"4"}},{"id":4531116,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Options","published_at":"2016-12-06T16:07:18.000Z","date":"2016-12-02","kind":"grant","acquired":true,"shares":75100,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":230000,"derivative":{"exercise_price":3.4,"exercise_date":"2019-12-02","expiration_date":"2026-12-01","underlying":"Common Stock","underlying_shares":75100},"source":{"system":"sec-edgar","filing":"0001662252-16-000276","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1224096/000166225216000276/form4.xml","form_type":"4"}},{"id":4531115,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Options","published_at":"2016-12-06T16:07:18.000Z","date":"2016-12-02","kind":"grant","acquired":true,"shares":75100,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":154900,"derivative":{"exercise_price":3.4,"exercise_date":"2018-12-02","expiration_date":"2026-12-01","underlying":"Common Stock","underlying_shares":75100},"source":{"system":"sec-edgar","filing":"0001662252-16-000276","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1224096/000166225216000276/form4.xml","form_type":"4"}},{"id":4531114,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Options","published_at":"2016-12-06T16:07:18.000Z","date":"2016-12-02","kind":"grant","acquired":true,"shares":75100,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":79800,"derivative":{"exercise_price":3.4,"exercise_date":"2017-12-02","expiration_date":"2026-12-01","underlying":"Common Stock","underlying_shares":75100},"source":{"system":"sec-edgar","filing":"0001662252-16-000276","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1224096/000166225216000276/form4.xml","form_type":"4"}},{"id":4531113,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":96177,"kind":"person","name":"EISENBERG JEFFREY F","position":1,"cik":"0001224096","reported_name":"EISENBERG JEFFREY F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Options","published_at":"2016-12-06T16:07:18.000Z","date":"2016-12-02","kind":"grant","acquired":true,"shares":4700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 2, 2016 the Issuer entered into an Employment Agreement with Mr. Eisenberg. Under the terms of the Employment Agreement, Mr. Eisenberg has the right to purchase 230,000 shares of common stock of the Issuer (the \"Option\") under the Issuer's Equity Incentive Plan, effective January 23, 2014 (the \"Plan\") at an exercise price equal to the fair market value of the Company's common stock on the grant date. 4,700 shares were granted pursuant to the Option were deemed vested immediately. The Options expire December 1, 2026."}],"balance_after":4700,"derivative":{"exercise_price":3.4,"exercise_date":"2016-12-02","expiration_date":"2026-12-01","underlying":"Common Stock","underlying_shares":4700},"source":{"system":"sec-edgar","filing":"0001662252-16-000276","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1224096/000166225216000276/form4.xml","form_type":"4"}}]}